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The present study aimed to establish if a previously identified Chlamydia trachomatis HtrA 
(CtHtrA) inhibitor, JO146, is effective against currently circulating clinical isolates to 
validate if CtHtrA is a clinically relevant target for future therapeutic development. Inhibition 
of CtHtrA during the middle of the chlamydial replicative cycle until the completion of the 
cycle resulted in loss of infectious progeny for six unique clinical isolates representing 
different serovars.  This supports the potential for CtHtrA to be a clinically relevant target for 
development of new therapeutics and suggests the importance of further investigation of 
JO146 as a lead compound.  
 
 




Chlamydia (C.) trachomatis is an obligate intracellular bacterial pathogen and is a 
commonly reported bacterial sexually transmitted pathogen worldwide. In the United States, 
over 1.4 million cases of C. trachomatis infection were reported in 2012, the highest number 
of cases ever reported to CDC for any condition [1].  
Currently, the recommended first line of treatment for uncomplicated genital C. 
trachomatis infections is a single 1.0 g oral dose of the macrolide antibiotic azithromycin [2]. 
However, a number of recently published studies challenge the efficacy of azithromycin 
therapy for chlamydial infections [3-6]. Batteiger and co-workers [6] conducted a cohort 
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study among adolescent women and used a classification algorithm to characterize treatment 
outcomes among the study subjects after directly observed azithromycin treatment. Among 
women with paired episodes of chlamydial infections, 8% were probable treatment failures. 
A partner treatment study conducted by Golden and co-workers [7] reported that 8% (22 of 
289 originally treated for Chlamydia) of cases treated reported no sexual intercourse after 
treatment and were classified as treatment failures. These studies suggest the possible future 
need for improved anti-chlamydial therapies.  
Our group identified a serine protease inhibitor, JO146, against C. trachomatis High 
Temperature Requirement A (CtHtrA) [8-11]. JO146 was found to be lethal to C. trachomatis 
D when added at the mid-replicative stage of the chlamydial developmental cycle [8]. The 
addition of JO146 was lethal during reversion or recovery from penicillin persistence and 
during heat stress [12].  
Laboratory strains of C. trachomatis that are commonly used for biological 
experiments may not reflect the isolates currently infecting men and women [13]. Differences 
in genome dynamics, and virulence attributes and infectivity [14-16] may result in varying 
sensitivities to JO146 between recent clinical isolates and the type strains of C. trachomatis 
used for investigations to date. Therefore, we aimed to validate that CtHtrA is a clinically 
relevant target for potential future therapeutic development by testing the efficacy of the 





2. Materials and Methods 
 
2.1. Clinical isolates, Chlamydia culture and J0146 treatment conditions 
Six C. trachomatis clinical isolates were obtained and cultured from separate women 
enrolled in the Australian Chlamydia Treatment Study (ACTS) [17] (The Alfred Human 
Research Ethics Approval number 223/12). The isolates were designated as: 1-017(13) 
(serovar K), 1-079(1) (serovar G), 1-019(1) (serovar D), 1-048(1) (serovar E), 1-028(1) 
(serovar E), and 1-020(1) (serovar D). The isolates were cultured in McCoy B cells grown in 
Dulbecco’s minimal essential medium (DMEM, Life Technologies) supplemented with 5% 
fetal calf serum (Lonza), 10 µg ml-1 gentamicin (Invitrogen), 100 µg ml-1 streptomycin 
sulphate (Sigma), incubated at 37oC, 5% CO2. For the purposes of this study, JO146 
(chemical formula: C31H44N3O7P) was commercially synthesised [18]. The compound was 
synthesised, HPLC purified, and confirmed by MALDI-MS by GL Biochem (Shanghai, 
China).  
The impact of JO146 on Chlamydia was determined in McCoy B cells infected at a 
multiplicity of infection (MOI) of 0.3 by centrifugation for 30 minutes at 500 × g at 28oC. At 
16 hours post infection (h PI), the cells were treated with JO146 (0, 10, 50 and 100 µM) and 
DMSO (solvent) control (all experiments were done in triplicate, at least two separate 
experiments, with one representative experiment shown). At the completion of experiment 
(44 h PI unless otherwise stated) Chlamydia was harvested into storage medium (sucrose 
phosphate glutamate (SPG): 10 mM sodium phosphate (Na2HPO4), 250 mM sucrose 
(C12H22O11), 5 mM L-glutamine (C5H10N2O3)) for subsequent determination of infectious 
yield (IFU ml-1 as described below).  
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The duration of treatment required for JO146 effect was determined by removal of the 
compound from the cultures after 8 h treatment. At 16 h PI C. trachomatis cultures were 
treated with either 0 µM (media only), 100 µM JO146, or DMSO. At 24 h PI (i.e. 8 hours 
after treatment) treatments were removed by three sequential washes with pre-warmed media 
and the cultures continued until harvest into SPG media at 44 and 68 h PI.  
Inclusion forming units (IFU ml-1) were determined by subsequent passage culture on 
McCoy B cells. The SPG harvested cultures were lysed by sonication (Ultrasonic, Microson) 
and serially diluted onto McCoy B cultures. At 30 h PI, cultures were fixed and stained using 
immunocytochemistry for host nucleus and chlamydial inclusions, and examined by 
microscopy to enumerate inclusion forming units [18].  
2.2 Confocal microscopy  
McCoy B cells infected with C. trachomatis cultured on coverslips were used for 
confocal microscopy. At nominated time points the cells were fixed and 
immunocytochemistry conducted as previously described [12]. Confocal images were 
obtained using an Olympus FV1200 confocal laser scanning microscope (FluoView® 
FV1200, Olympus Corporation, Japan). Sizes of 30 independent inclusions for each treatment 
and time point were measured manually through the use of NIS-Elements Basic Research 3.2 
software.  
2.3 Western blot  
Cultures of T25 flasks of McCoy B cells infected with C. trachomatis were harvested 
for western blot analysis of the Major Outer Membrane protein (MOMP) and host β-actin 
after JO146 treatment at 16 h PI and harvested at 24 h PI. Western blots were conducted as 
previously described [22].   
2.4 Statistical analysis 
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Statistical analysis was performed using PRISM (GraphPad Software Inc., V7.0). 
Statistical significance was defined as p < 0.05. Statistical tests used and number of samples 






3.1. HtrA inhibition using JO146 during McCoy B culture of chlamydial isolates prevents 
chlamydial inclusion vacuole size development 
Our previous work using HEp-2 cells on C. trachomatis D (UW-3/Cx) a long term 
passaged isolate (referred to here as CtD) demonstrated that the inclusions decreased in size 
and were lost from the host cells [18]. Therefore, here we examined the morphology of the 
McCoy B cultures of the clinical isolates at 20, 24, and 40 h PI after JO146 treatment (16 h 
PI). JO146 treatment resulted in smaller inclusion vacuole sizes than the DMSO treated 
control cultures (Supplementary Fig. S1). .  
Inclusions sizes were measured to quantify these observations. This difference in 
inclusion size was apparent at 24 h PI although only four clinical isolates (1-079(1), 1-
079(13), 1-019(1), and 1-028(1)) showed statistically significant differences (p < 0.01) in the 
size of inclusions compared to DMSO control at this time point (Fig. 1). At 40 h PI, 
Chlamydia inclusions in the presence of JO146 were smaller than those formed in the control 
(DMSO-treated cells) in all clinical isolates as well as for the C. trachomatis D (p < 0.0001) 
(Fig. 1).  
 
3.2. JO146 treatment during mid-replicative phase of chlamydial development in McCoy B 
cells  resulted in a loss of infectious progeny for clinical isolates 
The effect of 16 h PI JO146 treatment on the development of infectious progeny was 
tested. No infectious progeny (44 h PI) were observed for all clinical isolates treated with 50 
and 100 µM JO146 except for isolate 1-017(13) (Fig. 2). For isolate 1-017(13) treatment with 
50 µM JO146 resulted in approximately 1 log less infectious yield compared to DMSO and 
media controls (p<0.001) and 100 µM resulted in a complete loss of infectious progeny as 
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consistent with the other clinical isolates. Treatment of the type strain C. trachomatis D with 
50 and 100 µM JO146 both resulted in ~1.5 log less infectious progeny compared to that 
observed in the DMSO control (p < 0.0001) (Fig. 2).  
The reduction in infectious progeny and reduced inclusion sizes (Fig. 1) should 
correlate with a decrease in the detection of chlamydial protein. A western blot to detect 
levels of MOMP 8 h after JO146 treatment, showed a reduction of MOMP levels compared 
to matched DMSO controls for most of the isolates (Supplementary Fig.S2). 
 
3.3. JO146 requires long treatment times to be effective against C. trachomatis in McCoy B 
cultures 
In order to determine if JO146 activity against chlamydial clinical isolates is 
effective with a short duration of treatment, we removed JO146 from the cultures 8 h after 
addition. This resulted in recovery of infectious progeny at 44 and 68 h PI in all clinical 
isolates (Fig. 3) in contrast to complete loss of progeny when the compound was left in the 
cultures (Fig. 2). In C. trachomatis clinical isolates 1-028(1) and 1-019(1), there were fewer 
infectious EBs in cells treated with 100 µM JO146 compared to the cells treated with 0 µM 
JO146 (media only) and DMSO controls either at 44 or 68 h PI (Fig. 3). A non-significant 
increase was observed in the number of infectious progeny at 68 h PI compared to 44 h PI 
with 100 M JO146 for isolates 1-017(13), 1-079(1), 1-048(1) and 1-020(1) (Fig. 3). Overall, 
an 8 h JO146 treatment of the cultures resulted in a minor loss of infectious progeny 
compared to when the compound was left in the cultures until the end of the developmental 
cycle (Fig. 2), suggesting that in McCoy B cultures there is a need for longer treatment 






Here, we set out to determine if these previous observations of a critical function for 
HtrA during chlamydial replicative phase are relevant for recent clinical isolates of C. 
trachomatis. We demonstrate that addition of JO146 during mid-replicative phase resulted in 
a complete loss of infectious progeny if the compound is left in the cultures until the 
completion of the developmental cycle, providing preliminary support that the previous data 
in type strain cultures can be extrapolated to clinical isolates. 
These experiments were conducted in McCoy B cells, as consistent with other 
previously reported studies on C. trachomatis clinical isolates that all mainly use McCoy B 
cells (mouse fibroblasts) as host cells [19-21]. As we have not extensively studied the effect 
of JO146 on Chlamydia grown on McCoy B cells, we included C. trachomatis D as a control 
in all experiments. We previously demonstrated that treatment of HEp-2 cultures with the 
CtHtrA inhibitor JO146 resulted in diminishing chlamydial inclusion size, eventual loss of 
the inclusions, and loss of infectious progeny without being toxic to the host cells [8]. CtHtrA 
was found to be essential for the reversion and recovery to viability from penicillin 
persistence and during heat stress [12]. The critical role that CtHtrA plays during the 
replicative phase of the chlamydial developmental cycle was also demonstrated to be 
conserved among other C. trachomatis strains and other Chlamydia species such as C. 
pecorum, C. suis, and C. caviae [22]. The exact role of CtHtrA for the replicative phase 
remains unknown, and it is potentially and indirect effect of CtHtrA, and that one or more 
specific extra-cytoplasmic protein substrates that rely on CtHtrA for assembly is the required 
factor for replicative phase. 
The lack of lethality of 100 µM JO146 on type strain C. trachomatis D grown in 
McCoy B cells contrasts our previous result in HEp-2 cells, in which we observed complete 
loss of progeny for this same strain. These results suggest that there could be differences in 
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the pharmacokinetics of JO146 between mouse fibroblast (McCoy B) and human epithelial 
(HEp-2) cell lines, or in the chlamydial susceptibility during growth in these different cell 
lines. This difference also impacted on inclusion sizes actually sightly increasing over time 
during the cultures, again this may be due to differences in stability or degradation of JO146 
in the fibroblast cells. Previous studies have demonstrated different pharmacokinetics and 
bioactivity of drugs such as erythromycin in different mammalian cell lines [23, 24].  
In the present study the chlamydial inclusions were not completely lost from the host 
cells after JO146 treatment (in contrast to complete inclusion loss previously observed in 
HEp-2 cells), however these inclusions did not contain infectious progeny (Fig 1. and Fig 2.) 
[18]. Infectious progeny (with comparatively minor loss compared to controls) were observed 
for all strains tested when the cultures were treated with JO146 for 8 h at the replicative phase 
whereas there was lethality when the inhibitor was left in the cultures until the end of the 
developmental cycle. This result indicates that the inhibitory effect of JO146 is reversible by 
removal of the compound from the cultures and may be bacteriostatic, or may require longer 
than 8 h treatment to be effective in McCoy B cells. Here in McCoy B cells the inclusions fail 
to increase in size and do not make infectious progeny. This difference in the underlying 
process leading to loss of infectious progeny could be explained by several reasons; in these 
fibroblast-like cells perhaps the dosing is reduced due to cellular processes or once the 
Chlamydia in the inclusion have been inhibited by the JO146 treatment in HEp-2 a distinct 
host process than that of these fibroblasts is able to target the vacuoles. Nonetheless it is clear 
that CtHtrA is a valid possible target should future therapeutics need to be developed against 
Chlamydia, based on the effectiveness against these clinical isolates.  
The subtle differences in JO146 efficacy observed between the isolates and the type 
strain C. trachomatis D is not able to be explained by differences in CtHtrA amino acid 
sequence. The CtHtrA sequence is highly conserved with at most 4 amino acids different in 
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the 647 amino acid sequence across the published C. trachomatis genomes to date. The C. 
trachomatis genomes cluster into three predominant clades (LGV, T1, T2) [25], the CtHtrA 
sequences that we have determined so far from our clinical isolates are consistent with the T2 
clade (1-017(13), 1-017(1), 1-028(1), 1-048(1) (sequences will be published elsewhere). The 
amino acid variation is not near the residues that form active site where JO146 binds to the 
protein and is not likely to explain the variation. However, other differences that might 
impact on growth kinetics of pharmacokinetics of the drug on the chlamydial strains, as well 
as differences on the host cell factors do require further investigation in the future.  
 
5. Conclusions 
This preliminary study supports that JO146 is effective against recent clinical isolates 
of C. trachomatis. The data indicates that in vitro application of an inhibitor compound that 
targets CtHtrA during the replicative phase of recent clinical isolates of C. trachomatis 
prevents development of infectious progeny. CtHtrA therefore, could be a potential target for 
future drug development for C. trachomatis and we suggest that CtHtrA inhibition and JO146 
should be further investigated for improved drug development.  
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Fig. 1. Inclusion sizes at 20, 24 and 40 h PI for DMSO and JO146 treated isolates of C. 
trachomatis grown in McCoy B cells are shown in the graphs. Each isolate is shown in a 
separate graph: A. 1-017(13), B. 1-079(1), C. 1-028(1), D. 1-048(1), E. 1-020(1), F. 1-019(1), 
G. C. trachomatis D (UW-3/Cx). Statistical analysis was conducted using Two-Way 
ANOVA with Bonferroni’s multiple comparison tests. The bar colours represent treatment 
conditions; black: DMSO, and grey 100 M JO146. Data are presented as mean ± S.E.M 
(n=30), ** indicates p < 0.01, ****p < 0.0001.  
 
Fig. 2. Inclusion forming units after treatment with JO146 at 16 h PI or each of the strains is 
shown on the graph. The bars are shaded by grey scale (as indicated on the right) to represent 
the different concentrations of JO146. The identity of each of the isolates is indicated on the 
x-axis and the IFU ml-1 are indicated on the y-axis in log scale. The cultures were harvested 
at 44 h PI and the infectious progeny determined by measuring inclusion forming units that 
formed infections in a new monolayer of host cells. Statistical analysis was conducted using 
Two-Way ANOVA with a post hoc Bonferroni multiple comparison test relative to the 
DMSO control. Error bars represent the standard error of the mean (n=27) (non-logarithmic 
data), *** indicates p < 0.001, ****p < 0.0001. # indicates no detectable inclusion forming 
units. 
Fig. 3. Inclusion forming units ml-1 at 44 and 68 h PI after JO146 addition at 16 h PI and 
removal after 8 h (at 24 h PI). Conditions are represented by the coloured bars on the right 
(black: media only (0 M JO146), grey: DMSO, white: 100 M JO146). Each isolate is 
shown in a separate graph: A. 1-017(13), B. 1-079(1), C. 1-028(1), D. 1-048(1), E. 1-020(1), 
F. 1-019(1), G. C. trachomatis D (UW-E/Cx). The IFU ml-1 are indicated on the y-axis and 
the two time points (44 and 68 h PI) are indicated on the x-axis. The cultures were harvested 
at 44 h PI and the infectious progeny determined by measuring inclusion forming units that 
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formed infections in a new monolayer of host cells. Statistical analysis was conducted using 
Two-Way ANOVA with a post hoc Bonferroni multiple comparison test relative to the 
DMSO control. The error bars represent the standard error of the mean (n=27) (error bars are 








Supplementary Fig. S1. Confocal microscopy images of C. trachomatis clinical isolates 
treated with JO146 or DMSO at 16 h PI and examined at 20, 24, and 40 h PI. Representative 
images of control (DMSO treated) cultures are shown on the left panel while representative 
images of cultures treated with JO146 are shown on the right for each time point (time points 
indicated above figure) (strain identity indicated to left of the figure). The image colours are 
as follows, green; MOMP (major outer membrane protein); blue: host cell nucleus (stained by 
DAPI); red: β actin (stained by phalloidin 594). Scale bar (bottom left) indicates 10 µm.  
 
Supplementary Fig S2. Western blot for MOMP in cell lysates of JO146-treated and DMSO-
treated C. trachomatis clinical isolates in McCoy B cells. JO146 or DMSO were added at 16 
h PI and cells were harvested at 24 h PI (i.e. 8 hours after treatment). Treatments are 
indicated above each lane at the top of each isolate name. “+” denotes treatment with JO146 
and “-“ denotes treatment with DMSO control. Laboratory strain C. trachomatis D (UW-
3/Cx) (CtD) was included as a control strain. The size of relevant molecular weight markers 
are indicated to the right of the figure and the western blot identity (i.e. MOMP or β-actin) 
are indicated to the left.  
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